These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 4403351)

  • 1. The effect of cyclophosphamide on the ability of graft-versus-host reaction to suppress leukaemia in mice.
    Boranić M; Tonković I
    Rev Eur Etud Clin Biol; 1972 Mar; 17(3):314-20. PubMed ID: 4403351
    [No Abstract]   [Full Text] [Related]  

  • 2. Graft versus leukemia for "cell cure" of long-passage AKR leukemia after chemoradiotherapy.
    Saltzstein EC; Glasspiegel JS; Rimm AA; Giller RH; Bortin MM
    Cancer Res; 1972 Aug; 32(8):1658-62. PubMed ID: 4402951
    [No Abstract]   [Full Text] [Related]  

  • 3. Time pattern of the antileukemic effect of graft-versus-host reaction in mice.
    Boranić M; Tonković I
    Cancer Res; 1971 Aug; 31(8):1140-7. PubMed ID: 4398523
    [No Abstract]   [Full Text] [Related]  

  • 4. Transient graft-versus-host reaction in the treatment of leukemia in mice.
    Boranić M
    J Natl Cancer Inst; 1968 Aug; 41(2):421-37. PubMed ID: 4876445
    [No Abstract]   [Full Text] [Related]  

  • 5. Time pattern of antileukemic effect of graft-versus-host reaction in mice.
    Boranić M
    Transplant Proc; 1971 Mar; 3(1):394-6. PubMed ID: 4398494
    [No Abstract]   [Full Text] [Related]  

  • 6. Further development of a successful protocol of graft versus leukemia without fatal graft-versus-host disease in AKR mice.
    Chester SJ; Esparza AR; Flinton LJ; Simon JD; Kelley RJ; Albala MM
    Cancer Res; 1977 Oct; 37(10):3494-6. PubMed ID: 20223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of cyclophosphamide for clinical marrow transplantation.
    Santos GW; Sensenbrenner LL; Burke PJ; Mullins GM; Blas WB; Tutschka PJ; Slavin RE
    Transplant Proc; 1972 Dec; 4(4):559-64. PubMed ID: 4405147
    [No Abstract]   [Full Text] [Related]  

  • 8. Graft-vs-leukemia and moderation of graft-vs-host reaction in transplantation therapy of viral leukemia.
    Okunewick JP; Meredith RF; Raikow RB; Brozovich BJ; Magliere K
    Exp Hematol; 1981 Aug; 9(7):754-65. PubMed ID: 7032959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of secondary disease in leukaemic mice with host-type and third-party haemopoietic cells and blood.
    Boranić M
    Rev Eur Etud Clin Biol; 1970 Mar; 15(3):309-14. PubMed ID: 4392840
    [No Abstract]   [Full Text] [Related]  

  • 10. Graft-versus-leukemia. V. Absence of antileukemic effect using allogeneic h-2-identical immunocompetent cells.
    Bortin MM; Rimm AA; Rose WC; Saltzstein EC
    Transplantation; 1974 Sep; 18(3):280-3. PubMed ID: 4154022
    [No Abstract]   [Full Text] [Related]  

  • 11. [The conditioning of patients for the purpose of bone marrow transplantation. Recent results].
    Gluckman E
    Nouv Rev Fr Hematol; 1974; 14(4):531-3. PubMed ID: 4155495
    [No Abstract]   [Full Text] [Related]  

  • 12. An investigation into the influence of a graft-versus-host reaction, induced by parent line cells, on the growth of lymphoma transplants in F1 hybrid mice.
    Palmer AM; Symes MO
    Folia Biol (Praha); 1974; 20(1):26-35. PubMed ID: 4154872
    [No Abstract]   [Full Text] [Related]  

  • 13. Cyclophosphamide-induced graft-versus-host immunotolerance.
    Van Winkle MG
    J Reticuloendothel Soc; 1971 Nov; 10(5):403-17. PubMed ID: 4399566
    [No Abstract]   [Full Text] [Related]  

  • 14. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
    Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host and graft factors in the homing of haematopoietic cells.
    Hasek M; Nouza K
    Hamatol Bluttransfus; 1970; 9():79-85. PubMed ID: 4396278
    [No Abstract]   [Full Text] [Related]  

  • 16. Prolonged survival in long-passage AKR leukemia using chemotherapy, radiotherapy, and adoptive immunotherapy.
    Bortin MM; Rimm AA; Rodey GE; Giller R; Saltzstein EC
    Cancer Res; 1974 Aug; 34(8):1851-6. PubMed ID: 4152270
    [No Abstract]   [Full Text] [Related]  

  • 17. [The effect of the graft-versus-host reaction on transplantation immunity to homologous tumors].
    Semenkov VF; Shevelev AS
    Vopr Onkol; 1971; 17(6):69-73. PubMed ID: 4400328
    [No Abstract]   [Full Text] [Related]  

  • 18. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
    J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic resistance in the graft-versus-host reaction.
    Sula K; Nouza K
    Exp Clin Immunogenet; 1984; 1(3):175-84. PubMed ID: 6101099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of xenogeneic local graft versus host reaction by rat fetal spleen cells.
    Skowron-Cendrzak A; Rybczyńska Z; Sajak A; Dobrowolski Z
    Arch Immunol Ther Exp (Warsz); 1984; 32(4):443-6. PubMed ID: 6534317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.